Abstract
Low-grade gliomas are relatively rare tumors. The optimal management of these tumors remains to be defined and has some controversies associated with it. In this review, we present the data that is available to date and some of the issues that exist in treating these tumors.
Financial & competing interests disclosure
Jeffrey Raizer is on the Schering-Plough speakers bureau and also on advisory boards for Schering Plough and Genentech. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.
No writing assistance was utilized in the production of this manuscript.